WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.084
Volume 11, Issue 16, 658-666. Review Article ISSN 2277– 7105

# A REVIEW ON COMPUTER-AIDED DRUG DESIGN IN DRUG DISCOVERY

**Aditya Sumbe*[1], Dipak Sopane[2], Meghana Raykar[3] and Kumar Vanjari[4]**

[1,2,3,4]Department of Pharmacology, HSBPVT, GOI, College of Pharmacy, Kashti, Shrigonda, 413702, Maharashtra, India.

Article Received on
15 October 2022,

Revised on 04 Nov. 2022,
Accepted on 24 Nov. 2022

DOI: 10.20959/wjpr202216-26278

***Corresponding Author**
**Aditya Sumbe**
Department of Pharmacology, HSBPVT, GOI, College of Pharmacy, Kashti, Shrigonda, 413702, Maharashtra, India.

## ABSTRACT

Computer-aided drug design (CADD) is a developing field of study with numerous facets. In the interesting and varied field of computer-aided drug design (CADD), several facets of Basic and applied research converge and inspire one another. Quantum mechanics and molecular modeling research, including structure-based drug design, ligand- based drug design, database searching, and binding affinity based on knowledge of a biological target, are the theoretical underpinnings of CADD. We outline the areas where CADD tools enhance the drug discovery process in this review.

**KEYWORDS:** Computer-aided drug design, Molecular modeling, Biological target, Drug discoveryprocess.

## INTRODUCTION

The field of computer-assisted drug design (CADD) is a rapidly expanding one that covers a wide range of topics. The interesting and diversified field of computer-aided drug design (CADD) combines a variety of Fundamental and applied research interact and inspire one another. Theoretically, CADD is based on quantum mechanics and molecular modeling research such as structure-based drug design, ligand-based drug design, database searching, and bindingaffinity based on an understanding of a biological target. We discuss the areas in which CADD technologies assist the drug discovery process in this review. effectiveness and security of recently created medications. The major pharmaceutical corporations have made significant investments in the routine Ultra-High Throughput Screening (uHTS) of several compounds that are "drug-like."[3,4]

Parallel to this, computer-based virtual screening is being used more and more in medication

design and optimization.[5-7] The ability to conduct DNA microarray tests that examine thousands of illness-related genes has recently advanced our understanding of the disease targets, metabolic pathways, and medication toxicity.[8] Empirical molecular mechanics, quantum mechanics, and, more recently, statistical mechanics are some of the theoretical techniques available. This most recent development has made it possible to integrate explicit solvent effects. All of this work is made possible by the accessibility of high-quality computer graphics, which are primarily supported on workstations.[9]

**Two distinct categories of research are clearly distinguishable**

1) Crystallography, NMR, or homology modeling are three examples. The target macromolecule, the drug receptor, has a precise molecular structure that has been determined by x-ray.
2) The inconsistent activity of otherwise comparable substances.

Only by understanding both of these methods of approach will one be able to deduce the characteristicsof the target receptor binding site.

**Drug Discovery Process**

The process of finding new therapeutic molecules for the treatment or control of disease targets is known as drug discovery. To begin, many chemical compounds are screened to find the best disease targets. In order for the drug molecules to be adjusted to the binding site, it is necessary to have insightand knowledge about the structure of the drug receptor.




**Fig. 1: Drug disecovery process.**

Drug discovery process starts with understanding the disease for which the drug to be designed. Itconsists of the following steps.

1. **Candidate Drug Discovery**
- Selection of Therapeutic Target
- Lead Discovery
- Lead Optimization
2. **Preclinical and clinical trials to evaluate the safety, efficacy, and adverse effects of the drug**
- Animal studies
- Clinical trials
3. **FDA approval process for the newly discovered drug and bringing the drug to market for public use.**
- Additional post-marketing testing
- Further improvement of the drug

Pre-clinical development and the discovery of novel drugs often take 3-6 years. Before a product is sold on the market, it may take up to 10 years for the clinical trials to be completed.[10] A successful drug's market entry typically takes 12–15 years and more than $1.3 billion[11] About 250 of the 5000–10000 evaluated compounds on average are chosen for preclinical studies. Only 5 of them make it into clinical trials, and only one is approved by the FDA following a rigorous examination of the newly discovered medicine.

**CADD Strategies in the Drug Discovery Process**

Depending on the amount of structural and other information that is known about the target (enzyme/receptor) and the ligands, several CADD strategies are used. The two main modeling approaches utilized nowadays in the drug design process are direct and indirect design. The design in the indirect approach is based on a comparison of the structural characteristics of well-known active and inactive compounds. The target (enzyme/receptor-dimensional)'s characteristics are immediately taken into account in the direct design.

**Preparation of a Target Structure**

The quality and quantity of structural data that is known about the target and the small molecules thatare being docked are key factors in the success of virtual screening. Checking for an acceptable bindingpocket on the target is the first step.[12-13]

This is typically accomplished by analyzing existing target-ligand co-crystal structures or by employing in-silico techniques to locate brand-new binding sites.[14]

The optimal starting point for docking is a target structure empirically established by X-ray crystallography or NMR methods and placed in the PDB. The process of identifying target structures has sped up thanks to structural genomics. Several effective virtual screening campaigns based on comparison models of target proteins have been described in the absence of empirically confirmed structures.[15-17]

**Molecular dynamics-based detection**

Utilizing a single static structure to predict potential binding sites is occasionally insufficient due to the dynamic nature of biomolecules. Targets' structural dynamics are frequently accounted for by using a variety of target conformations. An ensemble of target conformations can be obtained starting from a single structure using traditional molecular dynamic (MD) simulations.

The MD technique calculates a protein's trajectory of conformations as a function of time using the laws of Newtonian mechanics. Traditional MD techniques frequently become stuck in local energy minima.

For traversing numerous minimum energy surfaces of proteins, improved MD algorithms have been constructed. These include targeted MD[20], conformational folding simulations[21], temperature-accelerated MD simulations[22], and replica exchange MD.[23]




**Figure 1.4: Steps involved in homology model building process.[38-39]**

**Monte Carlo Search with Metropolis Criterion (MCM) Simulations**

MCM samples conformational space more quickly than molecular dynamics since it only needs to evaluate the energy functions, not their derivatives. The randomness introduced by Monte Carlo permits hopping across the energy barriers, avoiding the system from becoming stuck in local energy minima, even when standard MD drives a system toward a local energy minimum. For flexible docking applications like MCDOCK, MCM simulations have been employed.[24]

**Genetic Algorithms**

Molecular flexibility is added by genetic algorithms through the recombination of parent and child conformations. The "fittest" or highest-scoring conformations in this artificial evolutionary process are preserved for a subsequent round of recombination. In this way, by preserving advantageous qualities from one generation to the next, the best collection of solutions can evolve. State variables in docking are a collection of values that describe the position of the ligand within the protein.

A set of values describing translation, orientation, conformation, amount of hydrogen bonds, etc. may be included in a state variable. The state is equivalent to the genotype, the ligand's resulting structural model in the protein is equivalent to the phenotype, and binding energy is equivalent to an individual's fitness. Gene operators may randomly exchange huge portions of a parent's genes.

**Empirical Scoring Functions**

Experimental data are fitted with parameters by empirical scoring functions. As an illustration, consider binding energy, which is calculated by weighing explicit hydrogen bond interactions. Entropy, desolvation effects, and hydrophobic contract terms. Empirical function terms are based on approximations and are easy to assess. Regression analysis employing experimental data derived from molecular data is used to determine the weights for various parameters.

Several commercially available docking suits, including LUDI[28], FLEXX[29], and SUPERFLEX, have utilized empirical functions.[30]

**Knowledge-Based Scoring Function**

The data in experimentally generated scoring functions are used to create knowledge-based

scoring complicated structures that are determined. They are developed on the basis of the notion that interatomic Distances that occur more frequently than usual distances signify beneficial connections. Conversely, interactions that are observed to occur less frequently are probably to become less frequent. affinity. To forecast binding affinity, several knowledge-based potentials have been devised.similar to PO.

## CONCLUSION

The multidisciplinary discipline of computer-aided drug design (CADD) draws researchers from pharmacology, medicine, and other fields to develop new tools and techniques or improve those already in use to aid in the drug development process. These strategies outperformed more traditional approaches in terms of efficiency at various phases of the drug discovery process, which decreased the cost and length of time needed to produce medicine. There are several CADD tools available that help with the drug development process.

## REFERENCES

1. Whittaker. The role of bioinformatics in target validation. Drug Discovery To-Clinical trial registration: a statement from the International Committee of Medical Journal Editors. Medical Journal of Australia, 2004; 181: 293-4.
2. Lengauer. Bioinformatics. From Genomes to Drugs. Wiley- VCH, Weinheim, Germany, 2002.
3. Lipinski. Lead and drug-like compounds: the rule-of-five revolution. Drug Discovery Today:Technologies, 2004; 1(4): 337-341.
4. Leeson P D, Davis A M, Steele J. Drug-like properties: Guiding principles for design – or chemicalprejudice? Drug Discovery Today: Technologies, 2004; 1(3): 189-195.
5. Hou T. Xu X. Recent Development and Application of Virtual Screening in Drug Discovery: AnOverview. Current Pharmaceutical Design, 2004; 10: 1011-1033.
6. Klebe G. Lead Identification in Post-Genomics: Computers as a Complementary Alternative. DrugDiscovery Today: Technologies, 2004; 1(3): 225-215.
7. Gisbert Schneider. Uli Fechner. Computer-based de novo design of drug-like molecules. Nature.Reviews. Drug Discovery, 2005; 4(8): 649-663.
8. Butte A. The use and analysis of microarray data. Nature Reviews Drug Discovery, 1(12): 951-960.
9. Richards W. G. Computer-Aided Drug Design Pure and Applied Chemistry, 1994; 6(68): 1589-1596.

10. Kitchen D B. Decornez H. Furr J R. Bajorath J. Docking and scoring in virtual screening for drug discovery: methods and applications. Nature reviews in drug discovery, 2004; 3: 935-949.
11. DiMasi J A. Grabowski H G. The cost of biopharmaceutical R&D: is biotech different? Managerial and Decision Economics, 2007; 28: 469-479.
12. Hajduk PJ, Huth JR, and Tse C. Predicting protein druggability. Drug. Discov. Today, 2005; 10: 1675-1682.
13. Fauman EB, Rai BK, and Huang ES. Structure-based druggability assessment-identifying suitable targets for small molecule therapeutics. Curr. Opin. Chem. Biol., 2011; 15: 463-468.
14. Laurie AT, Jackson RM. Methods for the prediction of protein-ligand binding sites for structure-based drug design and virtual ligand screening. Curr. Protein. Pept. Sci., 2006; 7: 395-406.
15. Becker OM, Dhanoa DS, Marantz Y, Chen D, Shacham S, Cheruku S, Heifetz A, Mohanty P, Fichman M, Sharadendu A. An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX00023) for the treatment of anxiety and depression. J. Med. Chem., 2006; 49: 3116-3135.
16. Warner SL, Bashyam S, Vankayalapati H, Bearss DJ, Han H, Mahadevan D, Von Hoff DD, Hurley LH. Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach. Mol. Cancer. Ther., 2006; 5: 1764-1773.
17. Budzik B, Garzya V, Walker G, Woolley-Roberts M, Pardoe J, Lucas A, Tehan B, Rivero RA, and Langmead CJ. Novel N-substituted benzimidazolones as potent, selective, CNS penetrant, and orally active M(1) mAChR agonists. Med. Chem. Lett., 2010; 1: 244-248.
18. Buchan DW, Ward SM, Lobley AE, Nugent TC, Bryson K, and Jones DT. Protein annotation and modelling servers at University College London. Nucleic. Acids. Res., 2010; 38: 563-568.
19. Martí-Renom MA, Stuart AC, Fiser A, Sánchez R, Melo F, and Sali A. Comparative protein structure modeling of genes and genomes. Annu. Rev. Biophys. Biomol. Struct., 2000; 29: 291-325.
20. Schlitter J, Engels M, Krüger P. Targeted molecular dynamics: a new approach for searching pathways of conformational transitions. J. Mol. Graph, 1994; 12: 84-89.

21. Grubmüller H. Predicting slow structural transitions in macromolecular systems: Conformational flooding. Phys. Rev. E. Stat. Phys. Plasmas. Fluids. Relat. Interdiscip. Topics, 1995; 52: 2893-2906.
22. Abrams CF, Vanden-Eijnden E. Large-scale conformational sampling of proteins using temperature- accelerated molecular dynamics. Proc. Natl. Acad. Sci. U.S.A., 2010; 107: 4961-4966.
23. Sugita Y, Okamoto Y. Replica-exchange molecular dynamics method for protein folding. Chem. Phys. Lett., 1999; 314: 141-151.
24. Liu M, Wang SM. MCDOCK: a Monte Carlo simulation approach to the molecular docking problem. J. Comput. Aided. Mol. Des., 1999; 13: 435-451.
25. Jones G, Willett P, Glen RC. A genetic algorithm for flexible molecular overlay and pharmacophore elucidation. J. Comput. Aided. Mol. Des., 1995; 9: 532-549.
26. Halgren TA. Merck molecular force field. 1. Basis, form, scope, parameterization, and performance of MMFF94. J. Comput. Chem., 1996; 17: 490-519.
27. Böhm HJ. The computer program LUDI: a new method for the de novo design of enzyme inhibitors. J. Comput. Aided. Mol. Des., 1992; 6: 61-78.
28. Rarey M, Kramer B, Lengauer T, Klebe G. A fast flexible docking method using an incremental construction algorithm. J. Mol. Biol., 1996; 261: 470-489.
29. Jain AN. Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. J. Med. Chem., 2003; 46: 499-511.
30. Shimada J, Ishchenko AV, Shakhnovich EI. Analysis of knowledge-based protein-ligand potentials using a self-consistent method. Protein. Sci., 2000; 9: 765-775.
31. Velec HFG, Gohlke H, Klebe G. DrugScore (CSD)-knowledge-based scoring function derived from small molecule crystal data with superior recognition rate of near-native ligand poses and better affinity prediction. J. Med. Chem., 2005; 48: 6296-6303.
32. DeWitte RS, Shakhnovich E. SMoG: De novo design method based on simple, fast and accurate free energy estimates. J. Am. Chem. Soc., 1997; 119: 4608-4617.
33. Mitchell JBO, Laskowski RA, Alex A, Forster MJ, Thornton JM. BLEEP-Potential of mean force describing protein-ligand interactions: II. Calculation of binding energies and comparison with experimental data. J. Comput. Chem., 1999; 20: 1177-1185.
34. Feher M. Consensus scoring for protein-ligand interactions. Drug. Discov. Today, 2006; 11: 421-428.
35. O'Boyle NM, Liebeschuetz JW, Cole JC. Testing assumptions and hypotheses for rescoring success in protein-ligand docking. J. Chem. Inf. Model, 2009; 49: 1871-1878.

36. Becker OM, Dhanoa DS, Marantz Y, Chen D, Shacham S, Cheruku S, Heifetz A, Mohanty P, Fichman M, Sharadendu A. An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX00023) for the treatment of anxiety and depression. J. Med. Chem., 2006; 49: 3116-3135.
37. Johnson MA, Maggiora GM. Concepts and Applications of Molecular Similarity, Wiley, New York, 1990.
38. Stumpfe D, Bill A, Novak N, Loch G, Blockus H, Geppert H, Becker T, Schmitz A, Hoch M, Kolanus W. Targeting multifunctional proteins by virtual screening: structurally diverse cytohesin inhibitors with differentiated biological functions. Chem. Biol., 2010; 5: 839-849.
39. Cramer RD, Patterson DE, Bunce JD. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc., 1988; 110: 5959-5967.
40. Kiaris H, Spandidos DA. Mutations of Ras Genes in Human Tumors. International Journal of Oncology, 1995; 7(3): 413-421.